Dear Nanomedicine actors/enthusiasts,
As you may know, NANOMED2020 is a Coordination and Support Action under the FP7-Health which started in September 2012 for a total duration of 18 months, involving seven partners across Europe including the ETP Nanomedicine (more information about NanoMed 2020 is to be found on the ETPN website at: http://www.etp-nanomedicine.eu/nanomed2020/public)
It is a unique opportunity to deliver concrete recommendations to the European Commission to push forward the field of nanomedicine under Horizon 2020 and to propose concrete actions to bring more nanomedicine products on the market via a value chain optimisation.
Amongst other activities, NANOMED2020 is currently focusing on:
- Identifying the key bottlenecks of the value chain to focus on to leverage the translational possibilities of the development process
- Federating the nanomedicine community and establishing a European landscape via mapping all relevant actors, projects and infrastructures.
The first results of such exhaustive mapping have come out after a first-phase consolidation, focusing on industrial players and SMEs. Overall more than 800 companies have been listed with potential interest and 500 with a more direct link/activity to nanomedicine.
In parallel, and to consolidate the nanomedicine landscape, a 10 minutes online questionnaire has been designed and approved to gather additional data and to deliver first insights into the main gaps and needs of the nanomedicine value chain.
All stakeholders (including academia, SMEs, large and pharmaceutical industries, research institutes, CROs, CMOs, characterisation centres) and fields of expertise (including drug delivery and regenerative medicine but not cosmetics), are invited to take part in this survey, as we hope to gather inputs from the whole nanomedicine community.
The overall resulting landscape will be a unique and tremendously powerful tool to stress the dynamism of the field and the importance to bring nanomedicine upfront at the European level.
Individual actors listed in the mapping would hence benefit of an increased visibility at the European level and of future matchmaking opportunities.
Please access the questionnaire here and be sure to take part in this worldwide mapping of nanomedicine actors and activities:
I stay at your disposal for any question you may have and would like to thank you in advance for your coming contribution in this important action. – Olivier Fontaine